TCGA-P3-A6T4-01A-11R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.014155251
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.380
- PROTEIN_SECRETION+0.200
- MYC_TARGETS_V2+0.110
- UV_RESPONSE_UP+0.100
- BILE_ACID_METABOLISM+0.090
- TNFA_SIGNALING_VIA_NFKB+0.070
- XENOBIOTIC_METABOLISM+0.050
- SPERMATOGENESIS+0.030
- NOTCH_SIGNALING+0.020
- HEME_METABOLISM+0.010
Top 10 suppressed
- E2F_TARGETS-0.550
- HEDGEHOG_SIGNALING-0.460
- G2M_CHECKPOINT-0.430
- ALLOGRAFT_REJECTION-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- IL2_STAT5_SIGNALING-0.360
- ANGIOGENESIS-0.350
- APICAL_JUNCTION-0.340
- MYOGENESIS-0.340
- UV_RESPONSE_DN-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2016961 | — | — | 0.817 |
| 2 | TCGA-CF-A5U8-01A-11R-A28M-07 | — | — | 0.785 |
| 3 | TCGA-GC-A3RD-01A-12R-A22U-07 | — | — | 0.772 |
| 4 | SRR8943008 | — | — | 0.769 |
| 5 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.767 |
| 6 | TCGA-CF-A27C-01A-11R-A16R-07 | — | — | 0.765 |
| 7 | 1d0437fc-c8ad-47be-822d-b95ad10f0e4a | — | — | 0.763 |
| 8 | AUR-AEPZ-TTM1-A-1-1-R-A742-41 | — | B | 0.761 |
| 9 | R58 | — | — | 0.759 |
| 10 | MDT-AP-2993 | Med | Medulloblastoma | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |